Intensive CV Risk Management Failed to Curb Subsequent Events
September 14, 2011|Internal Medicine
Author and Disclosure Information
FROM THE ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES
The ADDITION-Europe study is financed by multiple organizations based in the United Kingdom, Denmark, and the Netherlands, including national health services and research institutions, and via unrestricted grants from Astra, Bio-Rad, GlaxoSmithKline, HemoCue, Merck, Novo Nordisk, Pfizer, and Servier. Dr. Griffin has previously received lecture fees from GSK, Unilever, Eli Lilly, and MSD. Dr. Simmons reported no personal conflicts of interest.
